Page 201 - Haematologica-April 2018

Major bleeding associated with oral anticoagulants
among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost. 2016;116(5):975-986.
13. Wang SV, Franklin JM, Glynn RJ, Schneeweiss S, Eddings W, Gagne JJ. Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrilla- tion: new initiator cohort study. BMJ. 2016;353:i2607.
14. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115(21):2689- 2696.
15. Nielsen PB, Skjoth F, Sogaard M, Kjaeldgaard JN, Lip GY, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antag- onist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017;356:j510.
16. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb
Haemost. 2005;3(4):692-694.
17. Nieto JA, Solano R, Ruiz-Ribo MD, et al.
Fatal bleeding in patients receiving anticoag- ulant therapy for venous thromboembolism: findings from the RIETE registry. J Thromb Haemost. 2010;8(6):1216-1222.
18. Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intrac- erebral hemorrhage. JAMA. 2015; 313(8):824-836.
19. Xu Y, Schulman S, Dowlatshahi D, et al. Direct oral anticoagulant- or warfarin-relat- ed major Bleeding: characteristics, reversal strategies, and outcomes from a multicenter observational study. Chest. 2017;152(1):81- 91.
20. Becattini C, Franco L, Beyer-Westendorf J, et al. Major bleeding with vitamin K antago- nists or direct oral anticoagulants in real-life. Int J Cardiol. 2017;227:261-266.
21. Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani DJ. New oral anticoagulants and the risk of intracranial hemorrhage: tradi- tional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fib- rillation. JAMA Neurol. 2013;70(12):1486- 1490.
22. Connolly BJ, Pearce LA, Hart RG. Vitamin K antagonists and risk of subdural hematoma:
meta-analysis of randomized clinical trials.
Stroke. 2014;45(6):1672-1678.
23. Larsen TB, Skjoth F, Nielsen PB, Kjaeldgaard
JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anti- coagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;353: i3189.
24. Li L, Geraghty OC, Mehta Z, Rothwell PM, Oxford Vascular S. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treat- ment after vascular events: a population- based cohort study. Lancet. 2017;390 (10093):490-499.
25. Yao X, Abraham NS, Alexander GC, et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc. 2016;5(2). pii: e003074.
26. Graham DJ, Reichman ME, Wernecke M, et al. Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med. 2016;176(11):1662-1671.
27. Majeed A, Hwang HG, Connolly SJ, et al. Management and outcomes of major bleed- ing during treatment with dabigatran or warfarin. Circulation. 2013;128(21):2325- 2332.
haematologica | 2018; 103(4)
745